Unique Proteomic Signatures Distinguish Macrophages and Dendritic Cells by Becker, Lev et al.
Unique Proteomic Signatures Distinguish Macrophages
and Dendritic Cells
Lev Becker
1,4*, Ning-Chun Liu
1,4, Michelle M. Averill
2,4, Wei Yuan
1,4, Nathalie Pamir
1,4, Yufeng Peng
3,
Angela D. Irwin
1,4, Xiaoyun Fu
1,4, Karin E. Bornfeldt
2,4, Jay W. Heinecke
1,4
1Department of Medicine, University of Washington, Seattle, Washington, United States of America, 2Department of Pathology, University of Washington, Seattle,
Washington, United States of America, 3Department of Rheumatology, University of Washington, Seattle, Washington, United States of America, 4Diabetes and Obesity
Center of Excellence, University of Washington, Seattle, Washington, United States of America
Abstract
Monocytes differentiate into heterogeneous populations of tissue macrophages and dendritic cells (DCs) that regulate
inflammation and immunity. Identifying specific populations of myeloid cells in vivo is problematic, however, because only a
limited number of proteins have been used to assign cellular phenotype. Using mass spectrometry and bone marrow-
derived cells, we provided a global view of the proteomes of M-CSF-derived macrophages, classically and alternatively
activated macrophages, and GM-CSF-derived DCs. Remarkably, the expression levels of half the plasma membrane proteins
differed significantly in the various populations of cells derived in vitro. Moreover, the membrane proteomes of
macrophages and DCs were more distinct than those of classically and alternatively activated macrophages. Hierarchical
cluster and dual statistical analyses demonstrated that each cell type exhibited a robust proteomic signature that was
unique. To interrogate the phenotype of myeloid cells in vivo, we subjected elicited peritoneal macrophages harvested from
wild-type and GM-CSF-deficient mice to mass spectrometric and functional analysis. Unexpectedly, we found that peritoneal
macrophages exhibited many features of the DCs generated in vitro. These findings demonstrate that global analysis of the
membrane proteome can help define immune cell phenotypes in vivo.
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Introduction
Monocytes emigrate from blood vessels into tissue, where they
differentiate into a variety of specialized macrophage popula-
tions central to tissue homeostasis, immunity, and inflammation
[1]. Thus, macrophages exhibit marked phenotypic heterogene-
ity in vitro and in vivo [2,3]. Based on patterns of gene expression,
protein secretion, and function, they have been classified as
classically activated (M1) or alternatively activated (M2) cells.
The M1 phenotype is promoted by Th1 mediators such as LPS
and IFN-c and is characterized by the production of pro-
inflammatory cytokines and nitric oxide (NO) and by potent
anti-microbial activity [4]. In contrast, the M2 phenotype is
induced by Th2 mediators, typically IL-4 or IL-13 [5], and it
triggers expression of arginase, proteinases, and immunosup-
pressive factors. Hence, alternatively activated macrophages
participate in tissue remodeling after injury and help resolve
inflammation [5].
Monocytes also can differentiate into myeloid dendritic cells
(DCs), which play specialized roles in host defense and antigen
presentation [6–8]. Populations of myeloid DCs that express high
levels of TNFa and iNOS (Tip DCs) have been identified in
inflamed tissues [8], and they mediate innate defense against
bacterial pathogens. Moreover, recent studies demonstrate that
monocyte-derived cells localize to T cell areas of lymph nodes to
cross-present antigen, indicating that monocytes can develop
into cells that exhibit the critical immune features of DCs in vivo
[6].
It is currently difficult to distinguish DCs from macrophages
because there is little agreement about the utility of specific
markers for identifying distinct cell types in tissues [9]. Commonly,
only a limited number of proteins have been used to assign cellular
phenotype, and the specificity of such proteins for any given
subpopulation has not been rigorously demonstrated [9]. Mass
spectrometry has been widely used to investigate the proteomes of
macrophages and dendritic cells [10–12], but much less is known
about the plasma membrane proteomes of these cells. Moreover,
no studies have directly compared the proteomes of macrophages
and DCs.
In the current studies, we used mass spectrometry to probe the
plasma membrane proteomes of macrophages, polarized macro-
phages, and DCs. We used bone marrow-derived cells because
differentiation ex vivo permits the generation of relatively
homogeneous, well-characterized cell populations that have been
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33297studied by many investigators. To investigate the physiological
significance of the in vitro cells, we also determined the membrane
proteomes of elicited peritoneal macrophages harvested from wild-
type and GM-CSF-deficient mice. We found that macrophages
and DCs have different membrane proteomes and that their
protein expression patterns distinguish them in vivo as well as in
vitro.
Results
Tandem mass spectrometry (MS/MS) identifies proteins
that are greatly enriched in the plasma membrane of
myeloid cells
We focused our mass spectrometric studies on the plasma
membrane proteomes of macrophages and DCs for two reasons.
First, membrane proteins serve critical roles in a variety of
functions characteristic of this family of leukocytes, such as
phagocytosis, cell migration, and antigen presentation. Second,
plasma membrane proteins are well-positioned for flow cytometric
analysis, which is widely used to isolate and interrogate the
phenotypes of specific populations of immune cells in vivo.
To generate large numbers of macrophages (Fig. 1A), we
incubated bone marrow cells from C57BL/6J mice with colony
stimulating factor-1 (M-CSF; gene name Csf1). We term the
resulting adherent cells, which were harvested after 6 days in
culture, bone marrow-derived macrophages (BmMs). BmMs
were polarized into M1 or M2 macrophages by exposure for
24 h to IFN-c/LPS or IL-4, respectively. Differentiation to M1
or M2 macrophages was confirmed by using qRT-PCR to
interrogate the cells for expression of accepted M1-specific (Nos2,
Tnfa, Il12b)a n dM 2 - s p e c i f i c( Ym1, Arg1, Mrc2) genes (Fig. 1B)
[2,13]. The model system we used to generate macrophages and
DCs (below) was reproducible and has been used by many
investigators.
Membrane-associated proteins were biotinylated, affinity-isolat-
ed, and analyzed with LC-ESI-MS/MS. The resulting tandem
MS data were processed using three independent criteria
(Fig. 1C). To ensure high-confidence protein identification, we
used two Bayesian algorithms (PeptideProphet [14] and Protein-
Prophet [15]). To select for reproducible protein detection, we
required that each protein be detected in at least 5 of 6 biological
replicates in at least one cell type. To control for nonspecific
interactions with the biotin-affinity column, we excluded proteins
detected in samples prepared from unlabeled cells.
This approach identified 192 cell membrane-associated proteins
with high confidence (Table S1). Gene ontology analysis revealed
that 77% (148 of 192) of the proteins were known membrane-
associated proteins (p=10
215) and that more than half of those (79
of 148) had been previously localized to the plasma membrane
(p=10
219), indicating that our biochemical approach yielded a
subproteome that was greatly enriched in plasma membrane
proteins. The top three molecular functions were triphosphatase
activity (p=10
210), GTPase activity (p=10
26), and ATP-depen-
dent transport (p=10
25), while the top three biological processes
were antigen processing (p=10
210), endocytosis (p=10
27), and
cell adhesion (p=10
26), which are strongly linked to membrane
activities critical to immune cells. In contrast, gene ontology
analysis of proteins excluded by our analytical criteria revealed
that these contaminants corresponded to abundant cytoskeletal
(p=10
211) and cytosolic (p=10
26) proteins involved in house-
keeping functions such as actin-cytoskeleton organization
(p=10
210), translation (p=10
211), and glycolysis (p=10
29).
Dual statistical analyses identified a wide range of plasma
membrane proteins that are differentially expressed by
polarized macrophages
The plasma membrane proteome of BmMs contained numer-
ous proteins (e.g., F4/80, CD14, CD11b, and CD11c) that are
commonly used as macrophage-specific markers, both in vitro and
in vivo. However, the specificity of many of these markers has been
questioned [9]. To identify proteins that accurately distinguish the
various macrophage subtypes generated in vitro, we quantified
proteins by spectral counting (a measure of relative protein
concentration [16]) and analyzed the data using both the t-test and
G-test [17,18].
Our approach to defining protein expression patterns that are
specific to a particular cell phenotype is illustrated for M1
macrophages (Fig. 1D–F). We first compared protein expression
levels in M1 and M2 macrophages (Fig. 1D). This analysis
identified 41 proteins expressed at higher levels and 33 proteins
expressed at lower levels in M1 cells than in M2 cells (t-test,
p,0.05; G-test, G-statistic .1.5 or ,21.5; FDR=2.5%). We next
required that, for a given protein to be a marker of the M1
phenotype, its level also had to significantly differ between M1
macrophages and BmMs. This additional constraint eliminated
more than half of the 74 proteins that tentatively distinguished M1
from M2 macrophages (Fig. 1E). For example, ITGAL and
CSF1R were M1-specific (Fig. 1F) while CD14 and ITGAV were
not (Fig. 1G). Using this approach for all possible pairwise
comparisons of cells, we identified 86 proteins that distinguished
the various types of macrophages from each other (Fig. 1H;1 7
protein for BmMs; 36 proteins for M1 cells; 35 proteins for M2
cells; Table S2).
Hierarchical cluster and dual statistical analyses
demonstrate that macrophages and DCs have different
membrane proteomes
Recent studies suggest that in addition to giving rise to
macrophages, monocytes can also serve as precursor cells to
specific populations of antigen presenting dendritic cells (DCs) [6].
To interrogate the plasma membrane proteome of DCs, we
treated bone marrow precursor cells with GM-CSF (Fig. 2A) and
performed tandem MS analysis on proteins isolated from their
plasma membranes. Myeloid DCs (BmDCs) generated by
culturing bone marrow cells with GM-CSF (gene name Csf2) are
a model of immature DCs that share many functional character-
istics with their in vivo counterparts [19]. Consistent with previous
observations [19,20], cell sorting analysis demonstrated that
BmDCs had higher CD11c and MHC-II expression and lower
F4/80 expression than BmMs (Fig. 2B–C, Fig. S1).
Analysis of the membrane proteome of BmDCs revealed that
many of the proteins that appeared to be characteristic of BmMs
or M1 or M2 macrophages (Fig. 1D) were also expressed at
similar levels by BmDCs (Fig. 2D, Table S3). Examples of such
proteins include P2RX7 and CSF1R for M1 cells and MGL2 and
CD14 for M2 cells (Fig. 2E). Inclusion of the BmDC plasma
membrane proteome, therefore, substantially refined the signa-
tures identified for M1, BmM, and M2 macrophages (Table S3).
In addition, BmDCs expressed a set of 63 proteins that
distinguished them from the three macrophage subpopulations
tested (Fig. 2D). FER1L, MBC2, CD180, and MRC1 are
examples of such proteins (Fig. 2F).
These findings indicate that, while the plasma membrane
proteomes of BmDCs and polarized macrophages overlap
considerably, BmDCs express a large set of membrane proteins
distinct from those of macrophages. To further support this
Plasma Membrane Proteomes of Myeloid Cells
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33297Figure 1. The plasma membrane proteome of macrophages. Panel A: Bone marrow-derived macrophages (BmM) were derived from bone
marrow precursor cells of C57BL/6 mice cultured with M-CSF. Classically activated macrophages (M1) and alternatively activated macrophages (M2)
were derived from BmMs by treatment with IFN-c and LPS or with IL-4. Panel B: qRT-PCR of markers used to detect M1 and M2 macrophages. Results
(means and SEMs, N=6) were standardized to 18S, expressed relative to the cell type with the highest expression of each gene, and are
representative of 3 independent analyses. Panel C: LC-ESI-MS/MS analysis of plasma membrane proteins isolated from differentially activated
macrophages. Proteins were quantified by spectral counting (total number of peptides identified for a given protein) and subjected to sequential
criteria to identify 192 plasma membrane proteins that were reproducibly detected with high confidence. Panel D: Quantification of the membrane
proteomes of M1 and M2 macrophages. Differentially expressed proteins (red, upregulated; green, downregulated; gray, not significantly different)
were identified based on t-test and G-test statistics. Significance cutoffs (dashed lines; p,0.05 and G-statistic .1.5 or ,21.5) were determined based
on permutation analysis (estimated FDR,5%). Panel E: Quantification of the membrane proteomes of M1 macrophages and BmMs. Proteins
differentially expressed by M1 cells relative to both BmMs and M2 cells are indicated with colored dots (red, upregulated; green, downregulated).
Proteins differentially expressed by M1 and M2 cells (Panel D) but not differentially expressed by M1 and BmMs are indicated by gray dots. Panel F:
Examples of proteins that distinguish M1 cells from both BmM and M2 cells (CSF1R, ITGAL). Results (N=6 per group) are means and SDs. Panel G:
Examples of proteins that fail to distinguish M1 cells from both BmM and M2 cells (CD14, ITGAV). Panel H: Plasma membrane proteins differentially
expressed by M1 cells (36 proteins), M2 cells (35 proteins), and BmMs (17 proteins).
doi:10.1371/journal.pone.0033297.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33297Figure 2. The plasma membrane proteome of bone marrow-derived dendritic cells (DCs). Panel A: Bone marrow-derived dendritic cells
(BmDCs) were obtained by culturing bone marrow cells with GM-CSF. Panel B: Flow cytometric analysis of CD11c and F4/80 expression in BmDCs and
BmMs. Results are presented as a contour plot with 10% probability increments. Panel C: Cell-surface exp ression of MHC-II by BmDCs and BmMs as
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cells by hierarchical cluster analysis. This approach clearly
differentiated the various cell types (Fig. S2). Importantly, all
biological replicates within a given cell type were tightly clustered
and completely segregated from biological replicates across cell
types. Hierarchical cluster analysis further demonstrated that the
membrane proteomes of macrophages and BmDCs were more
distinct from one another than were those of M1 and M2
macrophages (Fig. S2).
Immunocytochemical analysis validates candidate
proteomic signatures of myeloid cells
Our proteomic analysis identified a large number of plasma
membrane markers that may identify myeloid cell phenotypes in
vitro and in vivo. While some of these markers are already in use,
most of the proteins that were enriched in the membranes of the
various cell types have not been described as macrophage/DC
markers. To validate our findings, we investigated the expression
levels of a variety of candidate protein markers (both previously
characterized and new) by mass spectrometry and immunocyto-
chemistry (Fig. 3, Fig. S3).
In general, the two methods were in excellent agreement for the
proteins we examined. As is well established, high levels of F4/80
protein were detectable on all macrophage subpopulations
(BmMs, M1, and M2) but not on BmDCs (Fig. 3A–B). In
addition, we found high levels of CD11c on both M2 macrophages
and BmDCs (Fig. 3A–B). These data further support the notion
that CD11c, often considered to be a DC marker, is not specific
for those cells [9]. Moreover, strong CD11b expression was
detected on the cell surface of all myeloid cells (Fig. 3A–B). With
respect to novel markers, immunostaining confirmed the increased
expression of the markers we identified by MS/MS (Fig. 3C–D,
Fig. S3): the a6 integrin subunit (ITGA6) for BmMs; transferrin
receptor (TFRC) for M2 cells; TNF receptor superfamily member
5 (CD40) for M1 cells; and extended synaptotagmin-1 (MBC2) for
BmDCs.
The plasma membrane proteomes of elicited peritoneal
‘‘macrophages’’ and BmDCs are remarkably similar
We next determined whether the proteomic signatures
generated from myeloid cells derived in vitro predicted myeloid
cell phenotypes in vivo. We therefore injected C57BL/6J-Ldlr
tm1Her
mice with thioglycolate, harvested elicited myeloid peritoneal cells
(eMPCs) from the peritoneum 5 days later, isolated the aherent
cells’ plasma membrane proteins with affinity chromatography,
and analyzed those proteins with LC-ESI-MS/MS.
Our analyses focused on eMPCs, which are widely used in
macrophage studies. Unexpectedly, we found that eMPCs
expressed 64% (41 of 64) of the proteins that were enriched in
BmDCs generated in vitro with GM-CSF. In contrast, eMPCs
failed to express any of the 24 M1 cell markers or 22 M2 cell
markers, and they expressed only 1 of the 5 BmM markers
(Fig. 4A, Table S4). The expression levels (quantified by MS/
MS) of representative membrane proteins are shown in
Figure 4C. Hierarchical cluster analysis confirmed that eMPCs
were similar to BmDCs and were distinct from the three
macrophage types (Fig. 4A–B).
Our data indicate that eMPCs are more similar to BmDCs than
any of the types of in vitro generated macrophage we investigated.
Because MS/MS analysis quantifies the average protein expres-
sion level across the entire population of cells, we cannot exclude
the possibility that the proteomic signature of eMPCs is comprised
of a weight-averaged signal from a highly heterogeneous mixture
of cells. To investigate this possibility, we examined CD11b, F4/
80, and CD11c expression by flow cytometry, an approach
previously used to assess cellular heterogeneity in this model
system [21]. This approach demonstrated a single population of
eMPCs (Fig. 4D–E, Fig. S1), suggesting that eMPCs harvested
from C57BL/6J mice represent are reasonably homogeneous as
assessed by these markers.
eMPCs are often regarded as ‘‘inflammatory macrophages’’
[22,23]. We therefore compared the expression of pro-inflamma-
tory cytokines by M1 macrophages, BmDCs, and eMPCs. We
found that eMPCs and BmDCs expressed similar levels of Nos2,
Il12b, and Tnfa mRNAs but that M1 macrophages expressed
higher levels (Fig. 4F).
Immunocytochemical staining with a panel of 8 antibodies to
markers of the different myeloid-derived cells demonstrated that
eMPCs, like BmDCs, stained positive for FER1L and MBC2. In
contrast, eMPCs and BmDCs did not react with antibodies for the
macrophage markers CD11a, CD40, ITGA6, STAB1, TFRC or
ITGB5 (Fig. 4G). Collectively, these findings indicate that eMPCs
strongly resemble DCs generated in vitro with GM-CSF and are
distinct from any macrophage population tested.
Generation of eMPCs is impaired in mice that are
deficient in GM-CSF
The overlap between the surface proteomes of cultured BmDCs
generated with GM-CSF and eMPCs raises the possibility that
GM-CSF contributes to the generation of eMPCs in vivo. To test
this hypothesis, we injected thioglycolate into peritonea of wild-
type and Csf22/2 (GM-CSF-deficient) mice and harvested cells 3
and 5 days later. We observed 80% fewer cells in the Csf22/2
mice than in the wild-type mice at both time points (Fig. 5A–B;
day 3, p=0.002; day 5, p=6 610
26), suggesting that GM-CSF
helps generate eMPCs in this model of sterile inflammation.
We next compared the plasma membrane proteomes of eMPCs
from Csf22/2 and wild-type mice. Dual statistical criteria (G-
test,21.5 or .1.5, t-test: p,0.05) identified 16 proteins that were
differentially expressed between wild-type and Csf22/2 eMPCs
(Table S5). Interestingly, the expression levels of 75% (12 of 16) of
these proteins in Csf22/2 eMPCs were consistent with a switch
toward a more macrophage-like (i.e., M-CSF-driven) phenotype
(Fig. 5C–D). In contrast, eMPCs isolated from Csf22/2 and
wild-type mice expressed similar levels of F4/80 and CD11c,
which are commonly used to differentiate macrophages from DCs
(Fig. 5E, Fig. S1).
We assessed the functional properties of eMPCs harvested from
wild-type and Csf22/2 mice. eMPCs isolated from Csf22/2
mice were significantly more efficient at phagocytosing fluorescein-
labeled E. coli (Fig. 5F; 2.5-fold increase; p=0.01, Student’s t-test).
In contrast, they were less able to cross-present antigen (Fig. 5G–
H; 15-fold reduction; p=0.001, Student’s t-test). Taken together,
these findings suggest that GM-CSF regulates both the number
assessed by flow cytometry. Panel D: The plasma membrane proteome of DCs. Upper Panel: Proteins expressed at similar levels by DCs and either M1
cells, M2 cells, or BmMs. Lower Panel: Proteins differentially expressed by DCs relative to M1 cells, M2 cells, and BmMs (G-test.1.5 or ,21.5 and t-test:
p,0.05). Red, upregulated; green, downregulated. Panel E: Examples of proteins expressed at similar levels by DCs and either M1 cells, or M2 cells.
Results (N=6 per group) are means and SDs. Panel F: Examples of plasma membrane proteins differentially expressed by DCs. Flow cytometry
experiments are representative of 3 independent analyses.
doi:10.1371/journal.pone.0033297.g002
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inflammation.
Discussion
We used mass spectrometry to provide a global view of the
proteomes of macrophages and DCs generated in vitro with M-CSF
or GM-CSF. Using stringent dual statistical criteria, we identified
106 proteins that were enriched in the membranes of the different
cell types generated in vitro. We also identified core sets of proteins
that distinguished all the macrophage types and DCs from each
other (Fig. 6).
Our data suggest that proteomics can distinguish macrophage
classes from each other and from DCs. They are also consistent
with the view that M-CSF and GM-CSF are major determinants
of the polarization/differentiation of myeloid cells in vivo [24].
Moreover, they provide direct in vivo evidence that GM-CSF is a
major phenotypic determinant of peritoneal myeloid cells of mice
challenged with thioglycolate, a classic model of sterile inflamma-
tion.
Certain of the proteins we identified are widely used as markers
of cell phenotype in vivo. For example F4/80 is generally regarded
as a marker for macrophages [7], and our proteomic analyses
detected much higher levels of F4/80 in the plasma membrane of
Figure 3. Immunocytochemical detection of plasma membrane protein markers. Expression levels of widely used plasma membrane
protein markers (Panels A–B) and newly identified markers (Panels C–D) of M1 cells, M2 cells, BmMs, and BmDCs were assessed by mass
spectrometry (Panels A,C) and immunocytochemistry (Panels B,D). For MS/MS, proteins were quantified by spectral counting and expressed relative
to the cell type with the highest expression level for each protein. Results are means and SDs. Cells were stained with antibodies specific to each
protein (red channel), counterstained with DAPI to visualize nuclei (blue-channel), and examined by confocal microscopy. Immunostaining and
microscopy were performed on the same day with identical microscope settings. Results are representative of 3 independent analyses.
doi:10.1371/journal.pone.0033297.g003
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used markers are not specific. One striking example is CD11c –
often used as a DC marker. Mass spectrometry and immunoflu-
orescence detected high levels of CD11c in the plasma membrane
of M2 macrophages. Indeed, recent findings demonstrate that
CD11c fails to discriminate between macrophage and DC
populations in vivo [25]. However, most of the proteins that were
enriched in the membranes of the various cell types have not been
described previously.
Because plasma membrane proteins are central to the critical
functions of macrophages and DCs, our findings suggest that
unique plasma membrane protein expression patterns not only
interrogate the phenotypes of myeloid cells but also form an
important basis for the cells’ distinct functional properties. Thus,
over 50% of the plasma membrane proteins we identified were
selectively expressed by one of the four myeloid cell types,
supporting the conclusion that polarized macrophages and DCs
fulfill distinct biological roles (Fig. 6).
In vivo, the phenotypes of macrophages and DCs are regulated
by complex, dynamic tissue environments, making it unlikely that
a limited number of markers can define myeloid cell heterogeneity.
Indeed, it is generally accepted that the utility of widely used
myeloid markers such as F4/80, CD11b, and CD11c is highly
tissue-dependent [9,26,27]. Proteomic signatures, on the other
hand, should be more effective tools for defining cell phenotype
because patterns of protein expression are more resistant than
single measurements to the highly complex and variable
environments macrophages and DCs encounter in vivo.
The power of using protein expression patterns to establish
myeloid cell phenotypes is highlighted by the remarkable
similarities we observed between the plasma membrane proteome
of DCs generated with GM-CSF and that of eMPCs isolated from
the inflamed peritoneum of mice. Similar findings were obtained
when BmDCs and eMPCs were clustered according to gene
expression patterns obtained from a meta-analysis of in vitro and in
vivo generated myeloid cells [28]. We also found that markedly
Figure 4. Mass spectrometric and immunohistochemical staining of thioglycolate-elicited peritoneal cells (eMPCs), polarized
macrophages, and DCs. Panels A–B: Hierarchical cluster analysis of eMPCs. Cells were harvested from the peritoneal cavity of C57BL/6J-Ldlr
tm1Her
mice 5 days after intraperitoneal injection with thioglycolate. Isolated plasma membrane proteins detected by LC-MS/MS analysis of eMPCs were
subjected to hierarchical cluster analysis, using the 107 proteins identified as differentially expressed by myeloid cells generated in vitro (Fig. 2).
Panel B: Relationships among eMPCs, M1 cells, M2 cells, BmMs, and DCs, as determined by cluster analysis. Panel C: Protein expression in eMPCs, M1
cells, M2 cells, BmMs, and BmDCs. Protein levels were quantified by MS/MS and spectral counting. Data are presented as means and SDs. Panels D–E:
Flow cytometric analysis of CD11b, CD11c, and F4/80 in eMPCs. Results are presented as contour plots with 10% probability increments. Panel F: qRT-
PCR analysis of M1 marker genes (Nos2, Il12b, Tnfa) in M1 macrophages, BmDCs, and eMPCs. Results (means and SEMs; N=6) were standardized to
18S levels and expressed relative to M1 macrophages. Panel G: Immunostaining of eMPCs. Cells were stained with antibodies (red channel) to plasma
membrane proteins differentially expressed by BmDCs (MBC2, FER1L), BmMs (ITGA6, STAB1), M2 cells (TFRC, ITGB5), and M1 cells (CD11a, CD40).
Nuclei were visualized by DAPI staining (blue channel). Immunostaining and microscopy were performed on the same day and with identical
microscope settings to experiments presented in Fig. 3D and Fig. S3. Results obtained for flow cytometry, qRT-PCR, and immunocotyochemistry are
representative of 3 independent analyses.
doi:10.1371/journal.pone.0033297.g004
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Functional characterization showed that cells isolated from
Csf22/2 mice were less able than those from wild-type mice to
cross-present antigen (a function classically ascribed to DCs) and
more able to phagocytose bacteria (a function classically ascribed
to macrophages).
These observations strongly suggest that correlates of the
myeloid DCs generated with GM-CSF in vitro also exist in vivo.
Moreover, they are consistent with previous studies showing that i)
thioglycolate induces peritoneal myeloid cells to express and
secrete GM-CSF [29], ii) thioglycolate-elicited peritoneal myeloid
cells emigrate to draining lymph nodes as inflammation resolves—
a classic property of DCs [9,30], and iii) thioglycolate-elicited
peritoneal cells can present antigens and stimulate T cell
proliferation [31].
Our proteomic analyses, together with functional analyses of
macrophages and DCs by many investigators [1–3,7], depict a
scenario in which M-CSF and GM-CSF support highly polarized
protein expression patterns that influence diverse biological
endpoints ranging from antigen presentation to cell motility,
phagocytosis, generation of reactive oxygen species, fatty acid
oxidation, and inflammation. Moreover, previous studies have
validated many of the functional differences predicted by our
proteomic data. For example, NADPH oxidase, a protein over-
expressed by BmDCs, has been assigned a key role in antigen
presentation by DCs in vivo [32]. Importantly, changes in the tissue
milieu would elicit corresponding changes in resident and
recruited myeloid cells. Consequently, cell types with customized
patterns of protein expression (and hence function) would be
generated, and such cells would be well-suited to meet the
dynamic demands of the local environment.
Collectively, our observations provide a rich proteomic
framework that should help investigators identify specific popula-
tions of macrophages and DCs in tissue so they can correlate
functions with the correct cellular phenotypes. By using patterns of
protein expression specific to each type of myeloid cell, it will now
be possible to more confidently extrapolate data from in vitro
experiments to more complex in vivo situations. As myeloid-derived
cells are implicated in autoimmune diseases, cancer, infection, and
many other conditions, our membrane proteome signatures should
help investigators identify the specific populations that are central
to the pathogenesis of those disorders.
Materials and Methods
Ethics Statement
All animal studies were approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
Washington (protocol 3437-01).
Differentiation of myeloid cells
Macrophages and DCs were derived from bone marrow of
C57BL/6 mice [19,33]. For proteomic analyses, bone marrow-
derived cells from the tibias and fibulas of 5 mice were pooled and
Figure 5. Analysis of eMPCs harvested from wild-type and GM-
CSF-deficient (Csf22/2) mice. eMPCs isolated from wild-type (wt)
and Csf22/2 mice were interrogated for cell number, function, and
protein expression. Panel A–B: Accumulation of eMPCs 3 days (Panel A)
and 5 days (Panel B) following intraperitoneal injection with thiogly-
colate. Results (N=6) are means and SEMs. Panel C: Plasma membrane
proteomic analysis of eMPCs isolated from Csf22/2 and wild-type mice.
Differentially-expressed proteins were identified using the t-test and G-
test (p,0.05 and G-statistic .1.5) and quantified using the spectral
index. Panel D: Proteins differentially expressed by eMPCs isolated from
Csf22/2 mice (see Panel C) were measured in BmMs and BmDCs and
quantified using the spectral index. Panel E: Cell surface CD11c and F4/
80 expression on eMPCs was assessed by flow cytometry. Results are
presented as contour plots with 10% probability increments. Panel F:
Phagocytosis of fluorescein-labeled E. coli by eMPCs. Results (arbitrary
units, AU; N=4) are means and SEMs. Panel G–H: Antigen cross-
presentation by eMPCs. Ovalbumin (0.2 mg/mL)-treated eMPCs were
incubated with CFSE-labeled spleen cells isolated from OT-I transgenic
mice. Levels of CFSE were assessed in OT-I T cells selected by flow
cytometry and expression levels of CD8 and Vb5 (Panel G). The division
index was calculated using FlowJo software. Results (N=4) are means
and SEMs (Panel H). Where applicable, p-values were derived using a
two-tailed Student’s t-test. Results obtained for eMPC quantification,
flow cytometry, phagocytosis and antigen cross-presentation are
representative of 3 independent analyses.
doi:10.1371/journal.pone.0033297.g005
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6 cells per flask; Corning). For
mRNA quantification or confocal microscopy, 2610
6 or 2.5610
4
bone marrow-derived cells were plated into 6-well plates (Corning)
or 8-well chamber slides (Nunc), respectively. BmDCs were
cultured at 37uCi n5 %C O 2 in RPMI medium containing 10%
FBS and 10 ng/mL of GM-CSF (R&D Systems). Macrophages
were cultured in low D-glucose (1 g/L) Dulbecco’s minimum
essential medium (DMEM) supplemented with 10% FBS and 30%
L cell-conditioned medium [34]. Medium was replaced on days 2
and 4 (with retention of floating and attached cells) and on day 6,
when floating cells were discarded. BmMs and BmDCs were
harvested on day 7. To induce M1 or M2 phenotypes, BmMs were
stimulated for 24 h with IFN-c (12 ng/mL; R&D Systems) and
LPS (5 ng/mL; Sigma) or for 48 h with IL4 (10 ng/mL; R&D
Systems).
Collection of thioglycolate-elicited peritoneal cells
C57BL/6J-Ldlr
tm1Her, Csf22/2, and wild-type mice on the
C57Bl/6J genetic background were injected with thioglycolate
(Sigma), and cells were harvested from the peritoneal cavity 5 days
after injection. The cells were washed with phosphate-buffered
saline (PBS), plated, and allowed to adhere at 37uC for 2 h in
serum-free DMEM. At the end of that period, cells were washed 3
times with PBS to remove non-adherent cells. eMPC numbers in
the peritonea of wild-type (N=6) and Csf22/2 (N=6) mice 3 or
5 days following thioglycolate administration were determined by
counting CD11b
HI expressing cells by flow cytometry.
Isolation of plasma membrane-associated proteins
Cell-surface proteins were isolated, using a membrane-imper-
meable, cleavable biotinylation reagent (N-hydroxysulfosuccini-
mide-SS-biotin; Pierce) to label primary amines of proteins [35].
Briefly, cells were biotinylated at 4uC for 1 h, harvested, and lysed.
Cell lysates were passed over neutravidin agarose resin, and the
retained proteins were eluted with 100 mM DTT. In parallel,
non-biotinylated cells were subjected to the same procedure to
identify proteins that bound nonspecifically to the resin. Eluted
proteins were alkylated with 125 mM iodoacetamide, and digested
overnight at 37uC with sequencing-grade trypsin (1:50, w/w,
trypsin/protein; Promega). Tryptic digests were mixed with acetic
acid (1:1, v/v), and extracted on a C18 column (HLB, 1 mL;
Waters Corp.) according to the manufacturer’s protocol. Fractions
containing peptides were dried under vacuum and resuspended in
0.3% acetic acid/5% acetonitrile (1 mg protein/mL).
Liquid chromatography-electrospray ionization-tandem
MS (LC-ESI-MS/MS)
Tryptic digests (2 mg protein) were injected into a trap column
(Paradigm Platinum Peptide Nanotrap, 0.15650 mm; Michrom
Bioresources, Inc.) and desalted for 5 min with 5% acetonitrile,
0.1% formic acid (50 mL/min). Peptides were eluted onto an
analytical reverse-phase column (0.1506150 mm, 5 mm beads;
Magic C18AQ, Michrom Bioresources, Inc.) and separated at a
flow rate of 1 mL/min over 180 min, using a linear gradient of 5%
to 35% buffer B (90% acetonitrile, 0.1% formic acid) in buffer A
(5% acetonitrile, 0.1% formic acid). Mass spectra were acquired in
the positive ion mode, using electrospray ionization and a linear
ion trap mass spectrometer (LTQ, Thermo Electron Corp.) with
data-dependent acquisition. MS/MS scans were obtained on the 8
most abundant peaks in each survey MS scan.
Peptide and protein identification
MS/MS spectra were searched against the mouse International
Protein Index (IPI) database (version, 2007/10/30) [36], using the
SEQUEST search engine with the following search parameters:
unrestricted enzyme specificity, 2.8 amu precursor ion mass
Figure 6. Plasma membrane protein signatures of myeloid cells identify unique cell functions. Gene ontology analysis of plasma
membrane proteins enriched in M1 macrophages, M2 macrophages, all macrophage types (BmM, M1, and M2), and BmDCs identifies functional
categories of proteins enriched in each cell type (p,0.05 with Benjamini-Hochberg correction). The top three functional annotations are presented
for each cell type along with three representative proteins.
doi:10.1371/journal.pone.0033297.g006
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alkylation, and variable Met oxidation. SEQUEST results were
further validated with PeptideProphet [14] and ProteinProphet
[15], using an adjusted probability of $0.90 for peptides and
$0.96 for proteins. Proteins considered for analysis had to be
identified in at least 5 (of 6) biological replicates of at least one
cellular phenotype. When MS/MS spectra could not differentiate
between protein isoforms, all were included in the analysis.
Protein quantification and statistical analysis
Proteins detected by LC-ESI-MS/MS were quantified by
spectral counting (the total number of MS/MS spectra detected
for a protein [16]). Differences in relative protein abundance were
assessed with the t-test and G-test [17]. Permutation analysis was
used to empirically estimate the FDR [37]. Significance cutoff
values for the G-statistic and t-test were determined using PepC
[18], a software package that maximizes the number of
differentially expressed proteins identified for a given FDR.
Hierarchical clustering
Spectral counts for each protein in each sample were
normalized to mean expression across all cell types, using
(SCX,N2SCX,AVG)/(SCX,N+SCX,AVG), where SCX,N represents
the spectral counts for a given protein (X) in a given analysis (N)
and SCX,AVG is the average spectral count for that protein across
all analyses. This equation normalizes relative protein expression
to a value between 21 and +1 [38]. Hierarchical clustering of
samples and proteins was performed using MultiExperiment
Viewer [39] with Pearson correlation as the distance metric and
average linkage clustering as the linkage method.
Functional annotation
Functional enrichments in Gene Ontology annotations in the
plasma membrane-associated proteome (relative to the entire
mouse genome) were identified using the Bingo 2.0 plugin in
Cytoscape (V2.5.2) [40]. Statistical significance was assessed using
the hypergeometric test with Benjamini-Hochberg correction [37].
qRT-PCR
To quantify mRNA expression, total RNA was isolated from
cells, using TRIzol Reagent (Invitrogen) and the RNeasy Mini Kit
(Qiagen). Total RNA (1 mg) was reverse transcribed, using the
iScript Select cDNA Synthesis Kit (Bio-Rad). The sequences for
sense strand and antisense strand PCR primers are provided in
Supplementary Material (Table S6). PCR amplification of cDNA
samples was performed using SensiMix SYBR (Bioline) on a
7900HT Fast Real-Time PCR system (Applied Biosystems).
Relative quantification of PCR products was based on value
differences between the target and 18S control, using the
22DDCT method [41].
Confocal microscopy
Macrophages, BmDCs, and eMPCs grown in 8-well chamber
slides (Nunc) were formalin-fixed (10 min at room temperature),
washed with PBS, and blocked with 1% bovine serum albumin
(BSA) overnight at 4uC. Cells were probed with primary
antibodies (0.5–1 mg/mL) in PBS containing 0.1% BSA for 2 h
at room temperature. Antibodies against murine CD11a (Abcam),
CD11b (Abcam), CD11c (Abcam), CD40 (Abcam), MBC2
(Abcam), F4/80 (Abcam), ITGA6 (Abcam), ITGB5 (Abcam),
MAC2 (Cedarlane), FER1L (Abcam), STAB1 (Santa Cruz), and
TFRC (Abcam) were used in this study. Slides were incubated with
appropriate TRITC-labeled secondary antibodies (1:500; Molec-
ular Probes), mounted in medium containing DAPI (Vector), and
visualized with a Nikon A1 confocal microscope. For each
antibody, all analyses of cells were performed on the same day
with identical exposure settings on the microscope. We were
careful to avoid signal saturation for the cell type with the highest
expression (based on proteomic quantification) of each protein.
Appropriate isotype controls tested specificity.
Flow cytometry
In some cases, cells were detached from culture plates with
8 mg/mL lidocaine and 5 mM EDTA for 10 min at 37uC. Cells
were incubated with specific antibodies for 30 min at 37uC with
the following fluorophore-labeled primary antibodies
(eBioscience): MHC class II-APC (I-A/I-E, 25 ng/10
6 cells), F4/
80-FITC (250 ng/10
6 cells), CD11b-PB (75 ng/10
6 cells), and
CD11c-PE (150 ng/10
6 cells). Cells were sorted with a FACS
Canto (BD Biosciences), and the data were analyzed with FlowJo
software (V. 8.8.6, Tree Star, Inc.). Appropriate isotype controls
tested specificity. FACS analyses represent all live cells as assessed
by propidium iodide or calcein blue staining (eBioscience).
Antigen cross-presentation assays
Thioglycolate-elicited peritoneal cells (0.5610
6/well; 24-well
plate, NUNC) isolated from wild-type or Csf22/2 mice were
incubated overnight at 37uC in serum-free DMEM containing 10-
fold serial dilutions of ovalbumin (2 mg/ml, 0.2, 0.02, and
0.002 mg/mL). At that time, macrophages were washed and
incubated with CFSE-labeled spleen cells (5610
6/well) isolated
from OT-I transgenic mice. Cells were co-cultured in RPMI
supplemented with 10% FCS, 50 mM b-ME for 3 days. OT-I T
cells were gated based on CD8 and Vb5 expression, and CFSE
dilution was analyzed by flow cytometry. The division index was
calculated using FlowJo software (V. 8.8.6, Tree Star, Inc.).
Phagocytosis assays
Phagocytosis of fluorescein-labeled E. coli bioparticles was
assessed using the Vibrant
TM Phagocytosis Assay Kit (Invitrogen),
as previously described [42].
Supporting Information
Figure S1 Flow cytometric analysis of myeloid cells.
Panel A: Bone marrow-derived macrophages (BmM) and
dendritic cells (BmDCs) were obtained by culturing bone marrow
cells with M-CSF and GM-CSF respectively. Flow cytometric
analysis of CD11c, F4/80, and MHC-II expression in BmDCs and
BmMs. Results are directly comparable to Figure 2B–C in the
main manuscript. Panel B: F4/80, CD11b, and CD11c
expression in thioglycolate-elicited myeloid peritoneal cells
(eMPC) isolated from C57BL/6 mice. Results are directly
comparable to Figure 4D–E in the main manuscript. Panel C:
Cd11c and F4/80 expression in ePMCs isolated from wild-type or
Csf22/2 (GM-CSF-deficient) mice. Results are directly compa-
rable to Figure 5E in the main manuscript. Where applicable,
results are presented as contour plots with 10% probability
increments.
(TIF)
Figure S2 The plasma membrane proteome classifies
myeloid cells. Panels A–B: Hierarchical cluster analysis.
Spectral counts for each protein (192 total) in each cell type were
normalized to the mean expression level across all four cell types
and analyzed by hierarchical clustering with Pearson correlation as
the distance metric and average linkage clustering as the linkage
Plasma Membrane Proteomes of Myeloid Cells
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B: Demonstration of clustering of cell types more clearly.
(TIF)
Figure S3 Immunocytochemical detection of plasma
membrane protein markers. Expression levels of newly
identified markers of M1 cells, M2 cells, BmMs and BmDCs was
assessed by mass spectrometry (Panel A) and immunocytochem-
istry (Panel B). For MS/MS, proteins were quantified by spectral
counting and expressed relative to the cell type with the highest
expression level for each protein. Results are means and SDs. Cells
were stained with antibodies specific to each protein (red channel)
and counterstained with DAPI to visualize nuclei (blue-channel)
and examined by confocal microscopy. Immunostaining and
microscopy were performed on the same day with identical
microscope settings. Results are representative of 3 independent
analyses.
(TIF)
Table S1 Plasma membrane proteins detected by LC-
ESI-MS/MS in myeloid cells. Bone marrow precursor cells
were differentiated into bone marrow-derived macrophages
(BmM), classically-activated macrophages (M1), alternatively-
activated macrophages (M2), and bone marrow-derived dendritic
cells (BmDC). Plasma membrane proteins for each cell type (N=6)
were isolated, analyzed by mass spectrometry, and quantified by
spectral counting, the total number of peptides identified by LC-
ESI-MS/MS analysis.
(XLSX)
Table S2 Identification of plasma membrane proteins
that distinguish amongst polarized macrophages. Protein
markers specific for each macrophage population tested (or
signatures) were identified based on both the t-test (p-value) and
G-test (G-statistic). Protein markers for a given cell type were
defined as those that were consistently up-regulated (G.1.5 and
p,0.05; red) or down-regulated (G,21.5 and p,0.05; green)
relative to all macrophage cell types tested. Statistical significance
cutoffs for the G-test and t-test were established by random
permutation analysis to ensure that the false-discovery rate ,5%.
(XLSX)
Table S3 Plasma membrane proteomics of bone mar-
row-derived dendritic cells (BmDC). Overlaps between
plasma membrane protein expression in BmDCs and the
macrophage signatures identified (see Fig. 1 and Table S2), as
well as the BmDC signature were identified based on the t-test and
G-test. Protein markers of BmDCs (BmDC signature) were defined
as those that were consistently up-regulated (G.1.5 and p,0.05;
red) or down-regulated (G,21.5 and p,0.05; green) relative to all
macrophage populations tested.
(XLSX)
Table S4 Plasma membrane proteomics of thioglyco-
late-elicited myeloid peritoneal cells (eMPCs). Overlaps
between plasma membrane protein expression in eMPCs and
BmMs, M1, M2, and BmDCs (highlighted in blue) were identified
based on the t-test and G-test. For example, overlaps between
eMPCs and the BmDC signature were defined as those proteins
for which expression in eMPCs (like BmDCs) is consistently up-
regulated (G.1.5 and p,0.05; red) or down-regulated (G,21.5
and p,0.05; green) relative to all macrophage populations tested.
(XLSX)
Table S5 Plasma membrane proteins differentially
expressed in Csf22/2 mice. eMPCs isolated from wild-type
(wt) and Csf22/2 mice were analyzed by mass spectrometry.
Differentially expressed proteins were identified by the t-test
(p,0.05) and G-test (G.1.5 or ,21.5). Red=up-regulated and
green=down-regulated in eMPCs isolated from Csf22/2 relative
to wt mice.
(XLSX)
Table S6 PCR primers used in this study.
(XLSX)
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